DEFEND 2: Durable-Response Therapy Evaluation For Early- or New-Onset Type 1 Diabetes.

Trial Profile

DEFEND 2: Durable-Response Therapy Evaluation For Early- or New-Onset Type 1 Diabetes.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Otelixizumab (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms DEFEND 2A; DEFEND-2
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Nov 2016 Results of urinary C-peptide analysis published in the Diabetic Medicine
    • 28 Mar 2012 Additional trial acronym (DEFEND 2A) identified as reported by European Clinical Trials Database (EudraCT2010-022549-59).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top